In a unit outside Crawley, engineers assemble incubators and ventilators destined for the smallest and most vulnerable patients in intensive care. Inspiration Healthcare Group makes the machines that keep premature infants alive in the first hours and days after birth, and it sells them to hospitals across dozens of countries, the NHS among them. Its half-year results, published this week, show revenue down eight per cent to £22 million, a fall attributed almost entirely to the absence of a one-off £6.5 million export order that flattered last year's comparative figures. Strip that out and the underlying business looks healthy: its core SLE product line grew 38 per cent, its ventilation subsidiary Airon expanded on the back of a new three-year US supply agreement, and distribution revenue climbed a further seven per cent.

This is a modest company by any measure, but its results say something sharper about the position British medical technology occupies within the government's stated ambitions. Ministers have repeatedly framed life sciences as a pillar of industrial strategy, the sector meant to combine export earnings with domestic health benefit, delivering both growth and NHS capability in one motion. Inspiration Healthcare is precisely the kind of firm that narrative depends on: a domestic manufacturer with real intellectual property, serving both the health service at home and paying customers abroad. Its revenue volatility this year illustrates why that dependency is riskier than the policy language suggests.

Export orders of the size that inflated last year's figures do not arrive on a predictable schedule. They are won through tendering cycles, currency movements, procurement timetables in foreign health systems, and relationships built over years. A single large contract can double a division's revenue one year and vanish the next without any change in the underlying quality or competitiveness of the product. For a company of this scale, that volatility is manageable, even survivable, because the core domestic and recurring international business continues to grow underneath it. But it is also a reminder that life sciences exporters are not simply extensions of NHS supply chains that happen to sell overseas. They operate on commercial cycles the health service does not control and cannot smooth.

That matters to NHS leaders and policymakers for reasons beyond sentiment about British manufacturing. Neonatal intensive care remains one of the more visible pressure points in the health service, with capacity constraints and workforce shortages in specialist units reported regularly by royal colleges and regulators. A resilient domestic supplier base for the equipment those units rely on is not incidental to service continuity; it is part of it. If firms like Inspiration Healthcare are to keep investing in UK-based manufacturing and research, government procurement and export support need to function as a coherent system rather than parallel tracks that occasionally intersect. The three-year US agreement behind Airon's growth this half-year shows what sustained, structured contracts can do for a manufacturer's stability. The NHS, by contrast, has a patchier record of offering the kind of long-term procurement certainty that lets suppliers plan investment with confidence.

There is also a lesson here for how the government measures success in life sciences. Export figures and revenue growth are useful indicators, but they can mask the underlying fragility of firms whose fortunes swing on individual contracts. A sector strategy built around headline export totals risks celebrating volatility as momentum. What sustains a domestic med-tech base through downturns in any single market is recurring, diversified revenue and predictable domestic demand, not one-off wins dressed up as trend lines.

Inspiration Healthcare's own outlook remains upbeat, with a stronger order book heading into the second half and management expecting to finish the year ahead of expectations. That is a reasonable, unremarkable outcome for a well-run firm navigating a lumpy order cycle. The more useful signal for Whitehall is what the results reveal about the mismatch between rhetoric and structure. A life sciences strategy that treats manufacturers as strategic national assets should be judged by whether it gives them the procurement stability to match that status, not by whether their export orders happen to land in the same financial year twice.

‍